ADC Pharmacology & DMPK Service
Computational Design Meets Wet-Lab Precision
Are you currently facing complex ADC developability bottlenecks, unpredictable in vivo clearance, premature payload release, or challenges in balancing payload toxicity with target selectivity? Our ADC Pharmacology and DMPK Services help you streamline your preclinical development, optimize drug-antibody ratios, and de-risk clinical translation through a seamlessly integrated pipeline of state-of-the-art computational modeling and rigorous wet-lab validation.
Discover How We Can Help - Request a Consultation!
Overview of Creative Biolabs' ADC Pharmacology and DMPK Services
Antibody-Drug Conjugates (ADCs) offer powerful therapeutic potential but present complex optimization challenges. Traditional empirical screening is often slow and prone to late-stage failure. While AI-driven multi-omics and multi-modal modeling have revolutionized target identification and PK prediction, computational design requires empirical confirmation. Creative Biolabs bridges this gap by integrating advanced AI with rigorous, high-throughput wet-lab validation. Our dual-loop approach empirically confirms in vitro stability, lysosomal cleavage kinetics, and in vivo pharmacokinetic behavior, ensuring that only the most viable candidates advance to clinical development.
Fig.1 PK and PD of ADC delivered via subcutaneous and intratumoral experiments.1
Core Technical Methods We Used
| Technical Method | Purpose |
|---|---|
| Hybrid LBA-LC/MS/MS Quantification | We utilize ligand-binding assays combined with high-resolution liquid chromatography-mass spectrometry to simultaneously measure total antibody, conjugated antibody, and free payload concentrations in complex biological matrices. |
| In Vitro Blood Matrix & Lysosomal Cleavage Profiling | Our assays empirically measure the rate of payload release in plasma, serum, and isolated lysosomes to verify linker stability and off-target risk. |
| Multi-Tissue Spatial Biodistribution | We deploy advanced radioisotope labeling and quantitative whole-body autoradiography to map the exact spatial accumulation of both antibody and payload in tumor nests versus normal tissues. |
| Physiologically Based Pharmacokinetic (PBPK) Modeling | We translate empirical preclinical data into human clinical outcomes using advanced mathematical models that account for target-mediated drug disposition (TMDD) and FcRn-mediated recycling. |
Table.1 Core technical methods used in Creative Biolabs.
How Creative Biolabs' ADC Pharmacology and DMPK Services Can Assist Your Project
Creative Biolabs provides a complete, translatable preclinical package. Our services resolve critical developmental questions: Does your AI-designed ADC release payload prematurely in circulation? Does it penetrate solid tumors effectively? What is its predicted human half-life? By matching our deep computational screening with wet-lab assays, we deliver high-resolution answers that empower your pipeline.
Explore Our Capabilities - Schedule a Consultation to Learn More!
Service Workflow
Estimated Timeframe
The typical timeframe for our end-to-end ADC Pharmacology and DMPK service ranges from 8 to 12 weeks. This schedule is heavily influenced by the complexity of the conjugation chemistry, the choice of animal models, and the depth of tissue distribution profiling requested.
Why Choose Us?
Collaborating with Creative Biolabs gives your biopharmaceutical program an unfair advantage. We eliminate the guesswork of ADC development by delivering a seamlessly unified pipeline where advanced computational insights are instantly validated by empirical biological data.
Key Advantages
✔ Unparalleled Prediction Accuracy: Our machine learning models, trained on extensive historical datasets, achieve a high correlation with actual in vivo clearance and half-life, minimizing blind animal testing.
✔ True Hybrid Integration: We do not just run algorithms; we operate high-throughput wet-labs. If our AI models detect a developability risk, our laboratory team can immediately run parallel physical evaluations to confirm or bypass the liability.
✔ Sophisticated Multi-Analyte Assays: Our advanced LC-MS/MS and hybrid LBA platforms allow the detection of ultra-low levels of free payload in circulation, ensuring safety profiling of your candidates.
Unlock the Benefits of Creative Biolabs Expertise - Request a Quote Today!
Core Technology
Our platform integrates three specialized software and chemical modules to deliver optimized, clinically viable candidates:
| Technology Module | Key Capabilities | Application in Our Service |
|---|---|---|
| Structural Developability Predictor | Utilizes 3D structural language models to analyze electrostatic surface potential, hydrophobic patches, and aggregation-prone regions of proposed antibody sequences. | Screens virtual antibody-payload pairs to filter out candidates with high liabilities of rapid clearance or poor solubility before laboratory synthesis. |
| Hybrid LBA-LC/MS/MS Bioanalytical Platform | Combines the high-affinity capture of ligand-binding assays with the exact mass determination of liquid chromatography-mass spectrometry. | Simultaneously quantifies total antibody, conjugated antibody, and free payload from a single micro-volume serum sample, tracking the exact rate of payload loss over time. |
| Radiolabeled Autoradiography & Mass Balance Platform | Quantitative Whole-Body Autoradiography (QWBA) | Tracks the definitive metabolic fate of the payload, validating tumor-specific localization and quantifying off-target accumulation in vital organs such as the liver, heart, and kidneys. |
Table.2 Core technologies in Creative Biolabs.
Frequently Asked Questions
Q: How do your AI models predict the in vivo half-life of an ADC before it is physically synthesized?
A: Our machine learning models use multi-modal feature learning. By combining sequence-based language representations with structural descriptors of the antibody surface, the model identifies subtle physical properties associated with rapid clearance. When paired with small-molecule descriptors of your linker-payload, the engine predicts the overall clearance profile.
Q: Why is wet-lab validation necessary if the AI design software shows optimal properties?
A: AI models operate on probabilities and historical data patterns. Biological systems, however, are incredibly complex; factors like microenvironmental pH changes, cell-surface antigen shedding, and variable lysosomal enzyme concentrations can lead to unexpected in vivo behaviors. Our wet-lab assays serve as a critical safety net, empirically proving that the AI-designed ADC behaves exactly as predicted under physiological conditions.
Q: What species are available for your in vivo PK and tissue distribution studies?
A: We routinely perform preclinical PK/PD evaluations in rodents (mice and rats) and non-rodents (including cynomolgus monkeys). For oncology targets, we highly recommend our tumor-bearing mouse models, which utilize either Cell Line-Derived Xenografts or Patient-Derived Xenografts (PDX) to represent human tumor antigen heterogeneity accurately.
Q: Can your bioanalytical platform distinguish between conjugated payload and free payload?
A: Yes. Our hybrid LBA-LC/MS/MS platform is designed to do exactly that. We capture the intact conjugate using anti-idiotypic or anti-payload antibodies to measure the conjugated payload concentration, while performing direct organic extraction to isolate and measure the absolute level of free, deconjugated payload in the same biological sample.
Q: How does Creative Biolabs handle hydrophobic payloads that are highly prone to aggregation?
A: Hydrophobic payloads present a massive developability challenge. We resolve this by running our Structural Developability Predictor to optimize the linker chemistry and conjugation sites. Our wet-lab team then performs physical size-exclusion chromatography (SEC-MALS) and hydrophobic interaction chromatography (HIC) to guarantee a stable, monomeric formulation.
Contact Us
Creative Biolabs is committed to accelerating your ADC therapeutic pipeline. By blending elite computational intelligence with robust, empirical wet-lab validation, we deliver translational data package clarity that de-risks your pathway to the clinic.
Contact Our Team for More Information and to Discuss Your Project
Reference
- Tang, Yubo, et al. "Real-time analysis on drug-antibody ratio of antibody-drug conjugates for synthesis, process optimization, and quality control." Scientific Reports 7.1 (2017): 7763. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1038/s41598-017-08151-2.